ARVN - Arvinas Holding Company, LLC

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+1.18 (+8.31%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.20
Bid6.00 x 1800
Ask199,999.98 x 1000
Day's Range14.00 - 16.14
52 Week Range13.70 - 21.25
Avg. Volume142,857
Market Cap497.558M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-37.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.33
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

    NEW HAVEN, Conn., Dec. 07, 2018 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented.

  • GlobeNewswire28 days ago

    Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference

    NEW HAVEN, Conn., Nov. 20, 2018 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G..

  • GlobeNewswire2 months ago

    Arvinas to Present at Two Protein Degradation Conferences

    NEW HAVEN, Conn., Oct. 23, 2018 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be.

  • GuruFocus.com2 months ago

    Arvinas Inc (ARVN) President and CEO John G Houston Bought $480,000 of Shares

    President and CEO of Arvinas Inc (NASDAQ:ARVN) John G Houston bought 30,000 shares of ARVN on 10/01/2018 at an average price of $16 a share.

  • MarketWatch3 months ago

    Arvin's stock soars in its public debut, after upsized IPO priced at top of expected range

    Shares of Arvinas Inc. soared in their public debut on the Nasdaq exchange, after the biopharmaceutical company's upsized initial public offering priced at the top of the expected range. The first trade was at $21 at 10:36 a.m. ET for 466,365 shares, or 31% above the $16 IPO price. The stock has pared some gains since to trade up 25%. The company had said earlier this month it planned to offer 6.7 million shares in the IPO, but raised it late-Wednesday to 7.5 million. The IPO pricing was at the top of the expected range of $14 to $16, as the company raised $120 million. The company could raise up to $138 million if the underwriters exercise all of the options granted to purchase additional shares. With 32.16 million shares outstanding after the offering, the IPO price values the company at about $514.5 million. The company has gone public at a time that the Renaissance IPO ETF has gained 3.4% over the past three months and the S&P 500 has tacked on 8.2%.

  • The Wall Street Journal3 months ago

    [$$] Biotech Arvinas Prices Upsized IPO at High End of Range

    Biotechnology startup Arvinas Inc. late Wednesday priced an upsized initial public offering of 7.5 million shares at $16 apiece, the high end of the expected price range.

  • GlobeNewswire3 months ago

    Arvinas Announces Pricing of Initial Public Offering

    NEW HAVEN, Conn., Sept. 26, 2018-- Arvinas, Inc., a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, ...

  • Benzinga3 months ago

    The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...